The planned Phase Ib study will evaluate the safety and efficacy of TIR-C and be conducted in Sweden.

“The submission of our Clinical Trial Application is a major milestone for Pharmability,” says Leo Holmgren, CEO of Pharmability. “It marks the moment our drug candidate moves from the laboratory toward patients. The robust preclinical data package gives us strong confidence as we prepare to evaluate the safety and efficacy of TIR-C in our first-in-human Phase Ib study in atopic dermatitis.”

TIR-C

TIR-C is a novel cutaneous immunomodulatory drug candidate designed to target the underlying mechanisms of atopic dermatitis. The planned Phase Ib study will be the first clinical study of TIR-C in patients with atopic dermatitis and is designed to assess its safety and tolerability, as well as to provide an early evaluation of efficacy.

The submission follows the completion of the company’s GLP toxicology programme, which established a favourable preclinical safety profile for TIR-C across both systemic and dermal assessments. Together with the company’s CMC and broader non-clinical work, these results form the regulatory foundation supporting the planned clinical trial.